Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension.
Brash L., Barnes GD., Brewis MJ., Church AC., Gibbs SJ., Howard LSGE., Jayasekera G., Johnson MK., McGlinchey N., Onorato J., Simpson J., Stirrat C., Thomson S., Watson G., Wilkins MR., Xu C., Welsh DJ., Newby DE., Peacock AJ.
Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170).